A. Atmaca

A. Rossi, F. de Marinis, M. Tiseo, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer

R. Wirtz, S. Al-Batran, E. Jäger, 2012, BMC Cancer.

A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors

F. Marmé, S. Al-Batran, O. Ottmann, 2016, BMC Cancer.

Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51.

D. Jäger, Yao-Tseng Chen, J. Karbach, 2002, Cancer immunity.

Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma.

J. Karbach, S. Al-Batran, E. Jäger, 2005, Cancer research.

Cancer Immunity (19 October 2007) Vol. 7, p. 16

D. Jäger, J. Karbach, L. Old, 2005 .

Efficient In vivo Priming by Vaccination with Recombinant NY-ESO-1 Protein and CpG in Antigen Naïve Prostate Cancer Patients

J. Karbach, L. Old, E. Jäger, 2010, Clinical Cancer Research.

Long-term Complete Remission Following Radiosurgery and Immunotherapy in a Melanoma Patient with Brain Metastasis: Immunologic Correlates

J. Karbach, S. Gnjatic, E. Jäger, 2014, Cancer Immunology Research.

Long-termComplete Remission Following Radiosurgery and Immunotherapy in aMelanomaPatientwithBrainMetastasis : Immunologic Correlates

J. Karbach, S. Gnjatic, A. Atmaca, 2014 .

Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas.

S. Al-Batran, E. Jäger, A. Atmaca, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Urine antibody against human cancer antigen NY-ESO-1.

D. Jäger, Yao-Tseng Chen, J. Karbach, 2002, Cancer immunity.

Dose Escalation Study for Defining the Maximum Tolerated Dose of Continuous Oral Trofosfamide in Pretreated Patients with Metastatic Lung Cancer

D. Jäger, S. Al-Batran, E. Jäger, 2004, Oncology Research and Treatment.

Nivolumab (nivo) ± ipilimumab (ipi) in advanced small-cell lung cancer (SCLC): First report of a randomized expansion cohort from CheckMate 032.

P. Ascierto, P. Ott, M. Hellmann, 2017 .

The validation of matrix metalloproteinase-9 mRNA gene expression as a predictor of outcome in patients with metastatic gastric cancer.

R. Wirtz, R. Hofheinz, J. Hartmann, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.

D. Jäger, P. Ascierto, P. Sharma, 2016, The Lancet. Oncology.

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.

Paolo A Ascierto, Ariella Sasson, Ryan Golhar, 2018, Cancer cell.

Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.

R. Hofheinz, J. Hartmann, J. Stoehlmacher, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.

C. Bokemeyer, S. Hollerbach, R. Hofheinz, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The validation of estrogen receptor 1 mRNA expression as a predictor of outcome in patients with metastatic non‐small cell lung cancer

J. Ficker, A. Hartmann, R. Wirtz, 2014, International journal of cancer.

A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer

K. Caca, S. Al-Batran, E. Jäger, 2013, British Journal of Cancer.

Imatinib mesylate for targeting the platelet‐derived growth factor β receptor in combination with fluorouracil and leucovorin in patients with refractory pancreatic, bile duct, colorectal, or gastric cancer—A dose‐escalation Phase I trial

G. Ehninger, S. Al-Batran, E. Jäger, 2007, Cancer.

Thoracic Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2022

T. Overbeck, A. Bleckmann, A. Atmaca, 2022, Oncology Research and Treatment.

Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032

M. Hellmann, V. Moreno, J. Eder, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.

L. Sequist, Keunchil Park, R. Doebele, 2019, The oncologist.

LUD01-014: Phase 1/2 study of chimeric monoclonal antibody cG250 in combination with vinblastine in patients with advanced renal cell carcinoma (ARCC).

J. Karbach, S. Al-Batran, A. Atmaca, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reduced Incidence of Severe Palmar-Plantar Erythrodysesthesia and Mucositis in a Prospective Multicenter Phase II Trial with Pegylated Liposomal Doxorubicin at 40 mg/m2 Every 4 Weeks in Previously Treated Patients with Metastatic Breast Cancer

N. Harbeck, G. von Minckwitz, J. Sehouli, 2006, Oncology.

Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial

S. Hövelmann, S. Al-Batran, T. Heinzel, 2007, British Journal of Cancer.

Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort.

P. Ascierto, P. Ott, M. Hellmann, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Tumor-infiltrating lymphocytes mediate complete and durable remission in a patient with NY-ESO-1 expressing prostate cancer

J. Karbach, H. Prisack, E. Jäger, 2023, Journal for ImmunoTherapy of Cancer.

The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial

G. von Minckwitz, J. Sehouli, U. Kleeberg, 2006, British Journal of Cancer.

Synergistic Effects of Valproic Acid and Mitomycin C in Adenocarcinoma Cell Lines and Fresh Tumor Cells of Patients with Colon Cancer

E. Jäger, A. Atmaca, K. Chow, 2006, Journal of chemotherapy.

Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas

Sebastian Harder, Dirk Jäger, D. Jäger, 2005, Breast Cancer Research.

1194MO Canakinumab (CAN) + docetaxel (DTX) for the second- or third-line (2/3L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 phase III results

B. Halmos, L. Paz-Ares, B. Cho, 2021, Annals of Oncology.

Afatinib with Concurrent Radiotherapy in a Patient with Metastatic Non-Small Cell Lung Cancer

S. Al-Batran, E. Jäger, A. Atmaca, 2014, Oncology Research and Treatment.